Period:
Draw Mode:
| Volume | 446 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ardelyx Inc | ARDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.02 | 0.51% | 3.94 | 04:43:39 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.92 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 12 | 446 | - | 0.4902 - 4.22 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:25:01 | formt | 366 | $ 3.94 | USD |
Ardelyx Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 813.58M | 206.49M | 204.97M | $ 52.16M | $ - | -0.43 | -3.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 4.20M | 3.20% |
Ardelyx News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.97 | 4.22 | 3.77 | 4.02 | 11,210,483 | -0.03 | -0.76% |
| 1 Month | 2.99 | 4.22 | 2.82 | 3.76 | 12,816,224 | 0.95 | 31.77% |
| 3 Months | 2.50 | 4.22 | 2.14 | 3.36 | 9,019,303 | 1.44 | 57.6% |
| 6 Months | 1.13 | 4.22 | 1.09 | 2.51 | 8,740,530 | 2.81 | 248.67% |
| 1 Year | 1.13 | 4.22 | 0.4902 | 2.07 | 6,029,063 | 2.81 | 248.67% |
| 3 Years | 5.42 | 9.23 | 0.4902 | 2.25 | 4,945,484 | -1.48 | -27.31% |
| 5 Years | 5.65 | 10.4343 | 0.4902 | 2.45 | 3,203,856 | -1.71 | -30.27% |
Ardelyx Description
| Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis. |